February 25th 2009 — A new joint guideline produced by the American Society of Clinical Oncology (ASCO) and the American Urological Association (AUA) has recommended chemoprevention for prostate cancer in healthy men.
Specifically, it recommends that asymptomatic men with a prostate-specific antigen (PSA) of 3.0 ng/mL or lower and who receive regular screening consider using a 5-alpha reductase inhibitor (5-ARI), such as finasteride or dutasteride, to help prevent prostate cancer.
According to the new guideline, published online on February 24th in the Journal of Clinical Oncology and scheduled to appear in the April issue of The Journal of Urology, men in this category might benefit from a discussion with their physicians about the benefits and risks of 5-ARIs for the prevention of prostate cancer.
In addition, patients currently using these agents to treat benign conditions, such as lower urinary tract symptoms, should discuss continuing this treatment to reduce their likelihood of developing cancer.
To find out more please click here
Login
Forgotten password